Clincosm LogoSign in Get a demo

Pharmacokinetics of Tasimelteon in Subjects With Renal Impairment and Matched Control Subjects With Relatively Normal Renal Function

Sponsor
Vanda Pharmaceuticals (Industry)
Overall Status
Completed
CT.gov ID
NCT01526746
Collaborator
(none)
32
Enrollment
3
Locations
3
Arms
4
Duration (Months)
10.7
Patients Per Site
2.7
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The purpose of this research study is to understand whether there is any difference in the amount of tasimelteon (including its breakdown products) in the blood of individuals with severe renal impairment compared to individuals who have normal renal function. The safety and tolerability of tasimelteon will also be assessed throughout this study.

Condition or Disease Intervention/Treatment Phase
Phase 1

Study Design

Study Type:
Interventional
Actual Enrollment :
32 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Basic Science
Official Title:
An Open-Label, Single-Dose, Parallel-Group Study to Compare the Pharmacokinetics of Tasimelteon in Subjects With Renal Impairment With That in Matched Control Subjects With Relatively Normal Renal Function
Study Start Date :
Feb 1, 2012
Actual Primary Completion Date :
Jun 1, 2012
Actual Study Completion Date :
Jun 1, 2012

Arms and Interventions

Arm Intervention/Treatment
Experimental: End Stage Renal Disease, dialysis

eGFR <15 ml/min/1.73m^2

Drug: Tasimelteon
20mg capsule, once
Other Names:
  • VEC-162

    • Drug: Tasimelteon
    20mg, once
    Experimental: Severe renal impairment

    eGFR < 29 ml/min/1.73m^2

    Drug: Tasimelteon
    20mg capsule, once
    Other Names:
  • VEC-162

    • Drug: Tasimelteon
    20mg, once
    Experimental: Healthy controls

    eGFR > 80 mL/min/1.73m^2 Matched to renally impaired subjects by age, gender, BMI, and smoking status

    Drug: Tasimelteon
    20mg capsule, once
    Other Names:
  • VEC-162

    • Drug: Tasimelteon
    20mg, once

    Outcome Measures

    Primary Outcome Measures

    1. Tasimelteon pharmacokinetic parameters (AUC, Cmax, Tmax) [Predose, 0.25, 1, 1.5, 2, 4, 6, 8, 12, 24, 30, and 36 hours post-dose]

    Secondary Outcome Measures

    1. Pharmacokinetic parameters (AUC, Cmax, Tmax) of tasimelteon metabolites M3, M9, M11, M12, M13, and M14 [Predose, 0.25, 1, 1.5, 2, 4, 6, 8, 12, 24, 30, and 36 hours post-dose]

    2. The percentage of tasimelteon and its metabolites that are removed by hemodialysis (AUC) [4, 6, 8 hours after dosing]

      paired arterial and venous samples

    3. The ratio of plasma protein bound versus unbound fractions of tasimelteon and metabolites M9, M11, M12, M13, and M14 [0.5 and 3 hours post dose]

    4. Safety and tolerability as measured by spontaneous reporting of AEs, and clinically significant changes in laboratory parameters, ECG parameters, and vital signs [36 hours]

    5. The Columbia-Suicide Severity Rating Scale will be used to assess suicidal behavior and ideation. [once per day at Screening (approximately day -7), Day -1 (baseline), Day 2 (end of study)]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 79 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:

    Groups 1-3

    1. Ability and acceptance to provide written informed consent;

    2. Men or women between 18 - 79 years, inclusive;

    3. Subjects with Body Mass Index (BMI) of >18 and <40 kg/m2 (BMI = weight (kg)/ [height (m)]2);

    4. Males, non-fecund females (i.e., surgically sterilized, if procedure was done 6 months before screening or subject is postmenopausal, without menses for 6 months before screening), or females of child-bearing potential using an acceptable method of birth control for a period of 35 days before the first dosing and have a negative pregnancy test at the screening and baseline visits; Note 1: Acceptable methods of birth control include any one of the following: abstinence, vasectomized sexual partner, hormonal methods (i.e. pill, hormonal IUD, Depo-Provera, implants, patch, intravaginal device [NuvaRing]), intrauterine device (IUD [copper banded coils]), diaphragm, cervical cap, or condom with spermicidal jelly or foam.

    5. Willing and able to comply with study requirements and restrictions;

    Groups 1- 2 (renal impairment)

    1. Subjects with renal impairment defined as

    2. Group 1: Stage 5 End Stage Renal Disease (ESRD) (eGFR < 15 mL/min/m2) requiring regularly scheduled dialysis and have been on a stable dialysis regimen for at least three months at baseline; OR

    3. Group 2: Stage 4 severe renal impairment (eGFR ≤ 29 mL/min/m2) but not requiring dialysis as calculated using the Modification of Diet in Renal Disease (MDRD) Equation (Appendix 18.3)

    4. Otherwise considered healthy in general as determined by past medical history, physical examination, vital signs, electrocardiogram, and laboratory tests at screening;

    5. Vital signs (after 3 minutes resting in a semi-supine position) which are within the ranges shown below.

    6. Body temperature between 35.0-37.5 °C;

    7. Systolic blood pressure between 100-180 mmHg;

    8. Diastolic blood pressure between 60-115 mmHg;

    9. Pulse rate between 40-100 bpm.

    Group 3 (healthy matched controls)

    1. Subjects in Group 3 must match in gender, smoking status, age (±10 years), and body mass index [normal BMIs (18.00-24.99), overweight BMIs (25.00-30.99) and obese BMIs (31.00-40.00)] to Group 1 and/or 2;

    2. Subjects must have normal renal function defined as eGFR ≥ 80 mL/min/m2 as calculated using the Modification of Diet in Renal Disease (MDRD) Equation (Appendix 18.3 );

    3. Subjects must be in good health as determined by past medical history, physical examination, electrocardiogram, laboratory tests and urinalysis;

    4. Vital signs (after 3 minutes resting in a semi-supine position) which are within the ranges shown below:

    5. Body temperature between 35.0 - 37.5 °C;

    6. Systolic blood pressure between 90 - 150 mmHg;

    7. Diastolic blood pressure between 50 - 95 mmHg;

    8. Pulse rate between 40 - 90 bpm.

    Exclusion Criteria:

    Groups 1-3

    1. Smokers (use of tobacco products in the previous 3 months) unable or unwilling to limit consumption to 10 cigarettes per day or less while checked into the inpatient facility.
    1. Note: Smoking will be a match criteria and the site should attempt to enroll an equal number of smokers and non-smokers into each group.

    1. Exposure to any investigation drug, including placebo, within 30 days or 5 half-lives (whichever is longer) of dosing;

    2. Donation or loss of 400 mL or more of blood within two months prior to dosing;

    3. Significant illness within the two weeks prior to dosing;

    4. Answer 'yes' to either Question 4 (Active Suicidal Ideation with Some Intent to Act, Without Specific Plan) or Question 5 (Active Suicidal Ideation with Specific Plan and Intent) on the "Suicidal Ideation" portion of the C-SSRS, or answer "yes" to any of the suicide-related behaviors (actual attempt, interrupted attempt, aborted attempt, preparatory act, or behavior) on the "Suicidal Behavior" portion of the Columbia Suicide Severity Rating Scale (C-SSRS); and the ideation or behavior occurred within the past 6 months;

    5. Functioning renal transplant;

    6. History within the past 2 years of clinically significant acute or chronic bronchospastic disease, including asthma and chronic obstructive pulmonary disease, treated or not treated;

    7. Treatment with any drug known to cause major organ system toxicity (e.g., chloramphenicol or tamoxifen) during the 60 day preceding the Screening visit;

    8. Participation in a previous BMS-214778/VEC-162 trial;

    9. History of drug or alcohol abuse as defined in DSM-IV, Diagnostic Criteria for Drug and Alcohol Abuse, within the 12 months prior to screening or evidence of such abuse as indicated by the laboratory assays conducted during the screening and baseline visits. A positive drug screen in Groups 1 and 2 is acceptable if there is documentation that subjects have been prescribed the corresponding medication;

    10. History of immunocompromise, including a positive HIV (ELISA and Western blot) test result;

    11. A positive Hepatitis B surface antigen (HBsAg) test result;

    12. Any surgical or medical condition which might significantly alter the absorption, distribution or excretion of any drug. The Investigator should be guided by evidence of any of the following:

    13. History of clinically significant inflammatory bowel syndrome, gastritis, ulcers, gastrointestinal or rectal bleeding;

    14. History of major gastrointestinal tract surgery such as gastrectomy, gastroenterostomy, or bowel resection;

    15. History of pancreatic injury or pancreatitis;

    16. History or presence of liver disease or liver injury as indicated by lab values such as SGOT, SGPT, GGT, alkaline phosphatase, or serum bilirubin 1.5 times greater than the upper limit of normal;

    17. Clinically significant ECG abnormalities or vital sign abnormalities at screening or a history of unstable, severe, or clinically significant cardiovascular disease (e.g., myocardial infarction within previous 6 months, unstable angina, cardiac failure, second/third degree atrioventricular block);

    18. Subjects taking any unapproved prescription or over-the-counter medications; all concomitant medications must be discussed with and approved by the sponsor prior to enrollment;

    19. A known hypersensitivity to tasimelteon or drugs similar to tasimelteon including melatonin;

    20. Pregnant or lactating females;

    21. Inability to swallow the study medication whole;

    22. Any other sound medical reason as determined by the clinical Investigator.

    Groups 1 - 2 (renal impairment)

    1. Subjects with clinically significant abnormal findings, not consistent with clinical disease, upon physical examination, ECG, or laboratory evaluation;

    2. Evidence of progressive renal disease within 4 weeks prior to screening;

    3. Acute renal failure or nephrotic syndrome;

    4. Current hematuria of urologic origin;

    5. Any significant change in chronic treatment medication as determined by the clinical Investigator.

    Group 3 (healthy matched controls)

    1. Use of unapproved prescription medication within 1 month of dosing and OTC medication within 14 days prior to dosing;

    2. History or presence of impaired renal function as indicated by abnormal (>ULN) creatinine or BUN values or abnormal urinary constituents (e.g., albuminuria).

    3. A positive hepatitis C test result.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Clinical Pharmacology of Miami, Inc. Miami Florida United States 33014
    2 Orlando Clinical Research Center Orlando Florida United States 32809
    3 DaVita Clinical Research Minneapolis Minnesota United States

    Sponsors and Collaborators

    • Vanda Pharmaceuticals

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Vanda Pharmaceuticals
    ClinicalTrials.gov Identifier:
    NCT01526746
    Other Study ID Numbers:
    • VP-VEC-162-1106
    First Posted:
    Feb 6, 2012
    Last Update Posted:
    Feb 17, 2014
    Last Verified:
    Feb 1, 2014
    Keywords provided by Vanda Pharmaceuticals
    End stage renal disease
    ESRD
    kidney disease
    renal impairment
    renal
    Additional relevant MeSH terms:
    Renal Insufficiency

    Study Results

    No Results Posted as of Feb 17, 2014